Solutions Are Necessary to Increase Real-World Prostate Cancer Drug Use
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel Prostate Cancer Treatment Options Inspire ‘Optimism,’ Expert Says
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
AI May Play a Big Role in Prostate Cancer Diagnosis, Treatment Selection
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Genomic Testing Cannot be ‘Ignored’ in Metastatic Prostate Cancer
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
Metastatic CSPC: Future Directions in Care
Before closing out their discussion on novel treatment approaches to metastatic CSPC, expert panelists share hope for further evolution in care.
Optimizing Genomic Profiling in mCSPC
Expert perspectives on the utilization of genomic profiling in patients with metastatic castration-sensitive prostate cancer to impact treatment decisions.
Is There a Role for Triplet Therapy in Low-Volume mCSPC?
A brief discussion on the use of doublet versus triplet therapy in patients with low-volume metastatic prostate cancer.
Selecting Between Doublet and Triplet Therapy in mCSPC
Expert panelists consider which factors would push them toward utilizing triplet therapy in patients with metastatic castration-sensitive prostate cancer.
Case 2: Triplet Therapy in a 59-Year-Old Man With mCSPC
Centering discussion on a patient case of high-volume metastatic CSPC, expert panelists review the option of triplet therapy based on the PEACE-1 trial.
Metastatic CSPC: Educating Patients on PSA Levels
Shared insight on optimal patient monitoring strategies while administering therapy for metastatic castration-sensitive prostate cancer.
Optimizing Patient Monitoring Strategies in mCSPC
Selecting Therapy for Low-Volume mCSPC
Panelists provide comprehensive insight on treatment strategies specific to the setting of low-volume metastatic prostate cancer.
Metastatic CSPC: Rationale Behind ADT + Apalutamide Therapy
Expert oncologists review the selection of apalutamide + androgen deprivation therapy in this patient scenario of metastatic castration-sensitive prostate cancer.
Toxicities and Drug-Drug Interactions With Frontline Therapies for mCSPC
A brief discussion on the toxicities and drug-drug interactions associated with frontline therapies in metastatic CSPC and when it would be appropriate to alter treatment to mitigate toxicity.
Factors in Selecting Frontline Therapy for Patients With mCSPC
Focused discussion on drug and patient factors that aid in the selection of frontline therapy for metastatic castration-sensitive prostate cancer.
Metastatic CSPC: Is There a Continued Role for Docetaxel in the Frontline Setting?
Shared insight on the frontline use of chemotherapy options for patients with metastatic CSPC in the context of AR-targeted therapies.
Case 1: Frontline Therapy in 63-Year-Old Man With High-Volume mCSPC
After reviewing a patient scenario of metastatic castration-sensitive prostate cancer, expert panelists break down frontline treatment options in this setting.
Advanced Urothelial Cancer: Updates in Frontline Systemic Therapy
CancerNetwork® recap of an Around the Practice event with Neeraj Agarwal, MD, Petros Grivas, MD, PhD, Guru Sonpavde, MD, Thomas Powles, MBBS, MD, MRCP
Metastases and Variant Histology in Urothelial Cancer
Thomas Powles, MBBS, MRCP, MD, leads the discussion on selecting chemotherapy vs immune checkpoint inhibitors in the adjuvant setting for a patient who has metastases in urothelial carcinoma as well as approaching therapy for variant histology.
Adjuvant ICI Therapy in Advanced Urothelial Cancer
Guru P. Sonpavde, MD, leads the discussion on the use of adjuvant nivolumab in metastatic urothelial carcinoma and the impact on the subsequent use of immune checkpoint inhibitors in recurrent disease.
Clinical Impact of Biomarkers on Advanced Urothelial Cancer
Petros Grivas, MD, PhD; Guru P. Sonpavde, MD; Thomas Powles, MBBS, MRCP, MD; and Neeraj Agarwal, MD, comment on the role of biomarker testing and its impact on the patient selection and approach to treatment for advanced urothelial carcinoma.
Using Avelumab Maintenance in Advanced Urothelial Cancer
Experts in bladder cancer discuss when it’s appropriate to use avelumab maintenance therapy both with and without progression of disease in advanced urothelial cancer.
Patient Case: 78-Year-Old Man With mUC
Petros Grivas, MD, PhD, presents the case of a 78-year-old man with PD-L1+ metastatic urothelial carcinoma, and the panelists share insight on their treatment approach for the given patient.
JAVELIN Bladder 100 Study in Advanced Urothelial Cancer
Thomas Powles, MBBS, MRCP, MD, reviews data and results from the phase 3 JAVELIN Bladder 100 trial for patients with locally advanced or metastatic urothelial cancer.
Role of Maintenance Therapy in Advanced Urothelial Carcinoma
Petros Grivas, MD, PhD; Guru P. Sonpavde, MD; Thomas Powles, MBBS, MRCP, MD; and Neeraj Agarwal, MD, provide insight on how they approach the patient selection of maintenance therapy in advanced urothelial carcinoma.
Carboplatin vs I/O in Cisplatin-Ineligible Urothelial Cancer
Experts in bladder cancer comment on the role of PD-L1 testing in the frontline setting for advanced urothelial cancer and its impact on the use of up-front carboplatin or immunotherapy.
Standard of Care for First-Line Advanced Urothelial Cancer
Petros Grivas, MD, PhD; Guru P. Sonpavde, MD; Thomas Powles, MBBS, MRCP, MD; and Neeraj Agarwal, MD, share their approach to frontline therapy for patients with advanced urothelial carcinoma and consider the impact of cisplatin eligibility.
Diagnosis of Advanced Urothelial Carcinoma
Bladder cancer experts discuss the importance of detecting early signs and symptoms leading to the diagnosis of advanced urothelial cancer.
Overview of Advanced Urothelial Carcinoma
Neeraj Agarwal, MD, leads the discussion on the typical patient presentation and major risk factors for urothelial cancer.
Second-Line Therapy Options in Metastatic Renal Cell Carcinoma
This video reviews the various treatment options for metastatic renal cell carcinoma in the second-line setting, including considerations for different toxicity profiles.
2 Clarke Drive Cranbury, NJ 08512